Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone Maintenance Treatment for Relapse Prevention in Schizophrenia
NCT00848432Phase 4Completed
- Sponsor
- Capital Medical University
- Start
- Dec 2002
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of risperidone in schizophrenia (3 arms), sponsored by Capital Medical University. Primary endpoint: Relapse at 1 year. Started Dec 2002; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00848432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00848432.